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The Advisory Committee on Immunization Practice (ACIP) of Thailand, established nearly 40 years ago
and currently consisting of 28 experts in immunization and related ﬁelds, develops written recommen-ractice (ACIP)
xpanded Program on Immunization (EPI)
hailand
dations to the Ministry of Public Health (MoPH) regarding vaccines and immunization. Through careful
review of available scientiﬁc data, compiled and analyzed by Working Groups set up to examine speciﬁc
topics, the ACIP makes recommendations concerning the inclusion of new vaccines into the national
immunization program, target groups and ages for administration, vaccine schedules, and precautions
and contraindications. This paper includes a description of the composition of the ACIP; the process that
the Committee uses to formulate recommendations, including required data; and areas for improvement.
 . Introduction and background
Thailand is a middle-income country in Southeast Asia with a
DP per capita of US$ 4115 [1], a population of about 65 million
nd a birth cohort of around 800,000. The public health infrastruc-
ure in Thailand is designed to cover the entire population, both in
ural and urban areas, with at least one community hospital in each
f the country’s 926 districts, and one health care center in each
ub-district. Secondary and tertiary care include general or provin-
ial hospitals and regional or university hospitals, respectively. The
xpanded program on immunization (EPI) is fully integrated into
hese basic health services.
Thailand ofﬁcially launched its nation-wide immunization pro-
ram (EPI) in 1977 by expanding and strengthening the existing
mmunization service infrastructure [2]. Currently, the Thai EPI
ncludes vaccines that cover the following10antigens: tuberculosis
BCG), hepatitis B, diphtheria, tetanus (TT), pertussis, poliomyeli-
is (OPV), measles, mumps, rubella, and Japanese encephalitis (JE)
Table 1) [3]. Apart from the infant EPI vaccines, ﬂu vaccine has
een given to health care workers since 2004 and to people with
ertain chronic diseases since 2008. There also have been a number
f changes in vaccines and schedules over the years (Table 2).
Abbreviations: ACIP, Advisory Committee on Immunization Practice; EPI,
xpanded Program on Immunization; WHO, World Health Organization.
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Vaccine procurement, technical support, and evaluation are
carried out by the EPI at national level, while responsibility for
implementing the program is decentralized to the country’s 76
provincial health ofﬁces.
The Thai Ministry of Public Health has established a number of
principles and policies concerning immunization. These include:
the right of all people to be protected from vaccine-preventable
diseases; the inclusion of immunization in the basic health services
package; and the provision of safe, high-quality immunizations to
all people free of charge. According to national policy, all public
sector hospitals and health care centers must provide all immu-
nizations included in the EPI schedule for free in well-baby clinics,
and only private hospitals and clinics may charge for these ser-
vices. Immunization services, along with other preventive and
curative services, are ﬁnanced by the National Health Insurance
Plan (NHIP), established in 2002 [4] for all persons not covered
by other health insurance plans (e.g., the social security scheme
for private sector employees and the government employee health
care scheme). This includes services provided both in the public
sector and those provided by private providers who participate
in the NHIP. Patients receiving immunizations from a private
health provider who does not participate in the national insur-
ance program, however, must cover the costs of the vaccination
themselves.
Open access under CC BY-NC-ND license.Fromavaccine coverage survey conducted in2008, the coverage
for BCG, the third dose of hepatitis B, the third DTP dose, the third
dose of OPV andmeasles among children less than 1 year of agewas
greater or equal to 98%. The survey also found that 95% of vaccinees
had received their EPI vaccines from governmental facilities [5].
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Table 1
Current Immunization Schedule of the Thai EPI.
Age Vaccines
Birth BCG+HB1
2 months OPV1+DTP-HB1
4 months OPV2+DTP-HB2
6 months OPV3+DTP-HB3
9–12 months Measles or MMR1
18 months OPV4+DTP4+ JE1-2
2.5–3 years JE3
4–6 years OPV5+DTP5+MMR2
12 years dT
Pregnant women dT1-2-3
EPI = Expanded Program on Immunization; BCG=bacille Calmette-
Cuérin; OPV=Oral Poliovirus Vaccine; HB=Hepatitis B Virus Vaccine;
DTP=Diphthera–Tetanus–Pertussis Vaccine; MMR=Mump–Measles–Rubellar
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Hib, rotavirus, Japanese encephalitis (JE) vaccines) [7–11].
T
V
B
Jaccine; JE = Japanese Encephalitis; dT =Diphtherria–Tetanus Vaccine for adoles-
ents and adults. The number following vaccines refers to the order of vaccine
oses.
This article describes the structure and functionof theThaiAdvi-
ory Committee on Immunization Practice (ACIP), and outlines the
rocess by which the Committee develops recommendations for
he national immunization program.
. Role of the Advisory Committee on Immunization
ractice
In Thailand, according to MoPH regulations, policy changes
egarding immunization of children and adults, including the intro-
uction of new vaccines, are authorized and issued by the MoPH.
he MoPH receives guidance from the ACIP, which issues recom-
endations. The Committee was established by the MoPH in 1970
8 years before the national EPI was created. The main reason the
ommittee was established was because health care profession-
ls graduating from different medical schools were using different
mmunization practices.
In 2001, the Thai ACIP became part of a larger national advi-
ory body, the Thai National Vaccine Committee (NVC). The NVC
as four subcommittees to advise on the development of policies
elated to immunization and vaccines: (1) Vaccine Research and
evelopment, (2) Vaccine Production, (3) Vaccine Quality Control,
nd (4) Immunization Practice [6].
The overall goal of the ACIP is to provide advice that will lead
o the reduction in the incidence of vaccine-preventable diseases.
he ofﬁcial terms of references for the ACIP stipulate that the Com-
ittee shall:
provide advice and guidance on vaccines and immunization to
the MoPH;
able 2
accines used in the Expanded Program on Immunization (EPI) over time.
1977–1981 1982–1986 1987–1991 1992–19
BCG BCG BCG×2 BCG
DTP×2 DTP×3 DTP×4 DTP×5
OPV×2 OPV×3 OPV×4 OPV×5
Measles Measles Measles
Rubella Rubella Rubella×
HB×3
JE×2
Typhoida Typhoida Typhoida –
TT×2 TT×2 TT×3
CG=bacille Calmette-Cuérin; OPV=Oral Poliovirus Vaccine; HB=Hepatitis B vaccine; DT
E= Japanese Encephalitis vaccine; dT=Diphtherria–Tetanus vaccine for adolescent and a
a Killed whole-cell parental vaccine.28S (2010) A104–A109 A105
• make recommendations on the inclusion of vaccines into the
EPI, appropriate immunization schedules and target groups, and
methods for administering the vaccines;
• suggest areas of research related to vaccines and the epidemiol-
ogyof vaccine-preventablediseases, and suggestpossible sources
of funding for this research;
• propose immunization policies to the MoPH and NVC; and
• appoint Working Groups to study speciﬁc issues.
TheACIP’swritten guidelines have undergone 15 revisions since
its inception to ensure that the Committee’s work remains relevant
to changing times.
3. Structure and membership of the ACIP
The current ACIP consists of 28 members: a Chairperson – who
is the Director of the Department of Disease Control (DDC) – and
27 members with expertise in a variety of disciplines, including
vaccinology, immunology, pediatrics, internal medicine, obstet-
rics, public health, infectious diseases, and preventive medicine.
According to the selection criteria, all Committee members must
be Thai citizens from either governmental or non-governmental
organizations. As shown in Table 3, ACIP members can be divided
into three groups: (1) those appointed in their ofﬁcial capacity by
virtue of their position within the Government (11 members); (2)
representatives of relevant professional associations (6 members);
and (3) those appointed in their individual capacity as experts (11
members).
TheSecretariatof theCommittee isheadedbyeither theDirector
of theBureauofGeneral CommunicableDiseases –underwhich the
EPI is managed – or a senior medical ofﬁcer within the DDC. The
EPI program manager and staff also serve as assistant secretaries.
Currently, there are no representatives from consumer or com-
munity groups on the Committee. There is also as yet no policy to
ensure balance on the basis of gender or ethnicity among Commit-
tee members. Vaccine producers and suppliers are not represented
on the ACIP. However, technical staff from vaccine production
companies may be asked to present data on the vaccine during
Committee meetings.
While there are no representatives from theWorldHealthOrga-
nization (WHO) on the Thai ACIP, the Committee beneﬁts from
and uses immunization-related recommendations and guidelines
issued by WHO in such documents as the guideline for introducing
new vaccines and WHO position papers for speciﬁc vaccines (e.g.,ACIPmembers do not have ﬁxed terms.While there is no formal
review process, all members are appointed, and nominees are pro-
posed by the Secretariat to the full Committee for approval. Final
approval is given by the Minister of Public Health.
96 1997–2001 2002–2007 2008–2009
BCG BCG BCG
DTP×5 DTP×5 DTP×2
OPV×5 OPV×5 OPV×5
Measles Measles Measles
2 MMR MMR MMR
HB×3 HB×3 DTP-HB×3
JE×2 JE×3 JE×3
– – Inﬂuenza
TT×3 dT×3 dT×3
P=Diphthera–Tetanus–Pertussis vaccine; MMR=Mump–Measles–Rubella vaccine;
dults. The number following “×” = the total doses of vaccines per series.
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Table 3
Current members of the Thai Advisory Committee on Immunization Practice, as of January 25, 2010.
Type of member
1. Member by position
Director General of the Department of Disease Control (DCC) Chair
An assigned Director Deputy of the Department of Disease Control Member
Director of the Vaccine Trial Center (VTC), Mahidol University Member
Director of Bureau of Epidemiology, Department of Disease Control Member
Director of the Division of Biological Products, Department of Medical Science Member
Director of the Division of Communicable Disease Control, Department of Health, Bangkok Metropolitan Administration (BMA) Member
Manager of Fund Administration, National Health Security Ofﬁce (NHSO) Member
Director of the National Vaccine Committee (NVC) Ofﬁce, Department of Disease Control Member
Director of the Division of Drug Control, Food and Drug Administration (FDA) Member
Director of the Bureau of General Communicable Disease, Department of Disease Control Secretary
Manager of the EPI program, Department of Disease Control Assistant Secretary
An assigned EPI program staff person, Department of Disease Control Assistant secretary
2. Representatives, from
Infectious Disease Association of Thailand Member
Pediatric Society of Thailand Member
Preventive Medicine Society of Thailand Member
The Royal College of Pediatricians of Thailand Member
The Royal College of Physicians of Thailand Member
The Royal Thai College of Obstretricians and Gynaecologists Member
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r3. Individual Experts
Eight pediatricians with speciﬁc specialty areas
One virologist
One preventive medicine expert
. Conﬂicts of interest
Since recommendations made by the ACIP may have implica-
ions for both the public and private sectors, including vaccine
anufacturers, all candidates who are nominated for ACIP mem-
ership undergo careful screening for potential conﬂicts of interest
efore their names are submitted for ﬁnal consideration. While
here are no written conﬂict of interest rules, the Secretariat and
CIP members consider any links that a nominee may have with
vaccine supplier or producer, such as owning stock in a vaccine
ompany or receiving grant funding from a vaccine producer. In
uch cases, the Committee makes a judgment on whether the rela-
ionship with the company is signiﬁcant enough to bias their views
nd affect their partiality, when deciding whether or not to accept
he nominee.
. The process of developing recommendations
.1. ACIP meetings
The ACIP meets at least once per year and there are often two
r three meetings in a single year, depending on the number and
omplexity of issues to be considered. However, there is no regu-
ar schedule for ACIP meetings. The Secretariat is responsible for
cheduling the meetings and the Chairperson then sends a letter to
ommittee members to invite them to attend. Prior to the meet-
ng, members are given an agenda listing issues to be considered.
genda topics can be proposed by members of the ACIP, as well
s by non-members, including MoPH ofﬁcials, university profes-
ors, representativesofWHOandother internationalorganizations,
accine industry representatives, and other stakeholders. The Sec-
etariat makes a decisions on whether to include a proposed topic,
ased on whether there are sufﬁcient data for the ACIP to consider
he topic, whether the topic is considered a priority, and if there is
ime available on the agenda to cover the topic during the meeting,
hich typically last one-half day..2. Scope of work of the ACIP
The Committee makes recommendations on a variety of issues
egarding vaccines and immunization. These include the intro-Member
Member
Member
duction and use of new vaccines, vaccine schedules, vaccines for
high-risk groups (e.g., ﬂu vaccine for health care workers), vaccines
beyond the infant immunization schedule (e.g., for travelers, ado-
lescents, adults and certain types ofworkers), vaccine formulations
(e.g., multivalent vs. monovalent), and choice of vaccines for a spe-
ciﬁc disease (e.g., Jeryl Lynn vs. other strains of mumps vaccine).
The ACIP also recommends additional studies to conduct in order
to aid decision-making, such as to estimate the local disease bur-
den or vaccine cost-effectiveness. Examples of issues addressed in
recent ACIP meetings and the recommendations made are shown
in Table 4.
Meeting topics may include items that do not require a
review but are presented for informational purposes. These top-
ics may include epidemiological data on vaccine-preventable
diseases, including updates on disease outbreaks; safety, efﬁ-
cacy, effectiveness or cost-effectiveness of a vaccine; data
on a vaccine still in development; information on vaccines
that are newly licensed by the Thai FDA and could be con-
sidered for the EPI in the future; or changes in vaccine
supply.
5.3. Working Groups
Ad hoc Working Groups are frequently formed by the ACIP
to gather, analyze and prepare information on a speciﬁc topic,
such as the introduction of a new vaccine into the EPI, for
presentation to the full Committee. Sometimes, a single indi-
vidual is assigned this role. The Working Group members or
individual experts can be ACIP members or outside experts,
and are chosen for their expertise and experience (there are no
strict rules for assigning Working Group chairpersons or mem-
bers). While there are no rules against appointing foreigners
to Working Groups, no non-Thais have been Working Group
members in the past. These temporary Working Groups typi-
cally disband once decisions regarding their topic are made and
there are no permanent Working Groups. The Working Group
or individual expert present their ﬁndings and draft recom-
mendations or options to the ACIP in a closed meeting. ACIP
members then fully consider the information until a consensus is
reached.
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Table 4
Examples of issues addressed and recommendations made at recent meetings of the Thai ACIP.
Meeting date Issue to be considered Recommendation made by the ACIP Status of implementation (as of January
2010)
17 July 2009 Immunization policy for health care
workers
Establish expert group to draft policy for
consideration by the ACIP
The policy has been drafted and is
expected to be included in the next ACIP
meeting for consideration
What vaccines to add to the list required
for foreign-born children living in Thailand
(besides BCG, DTP, OPV and measles)
Add hepatitis B and JE to the list of
required vaccines for foreign-born children
The recommendation will be implemented
in Fiscal Year 2010
18 September 2009 Prioritizing groups to receive the 2009
H1N1 ﬂu vaccine, once available
Establish small expert group to draft
proposal to identify priority groups for the
vaccine for consideration by the ACIP
(based on data on vaccine characteristics
and performance, estimated incidence and
mortality rates of different risk groups, and
estimated population size of each group)
The expert group’s proposals were
accepted and vaccination for the
recommended groups started in January
2010
17 July 2008 Hib vaccine introduction Not to introduce Hib vaccine (mainly
because members doubted the estimate of
the burden of Hib pneumonia)
Hib vaccines are available in private
facilities and some governmental facilities
and vaccinees have to pay for them
Possible change in target ages for measles
vaccination
Keep the age for the ﬁrst measles dose at
9–12 months and decrease the age for the
second dose (using MMR) from 7 to 4 years
The revised schedule to include the second
dose of MMR has been included in the
immunization reference manual and
ofﬁcial letters sent to health facilities
requesting them to follow the
recommendation
Whether to consider the use of the live
attenuated SA 14-14-2 JE vaccine in place
of mouse-brain derived vaccine used in the
EPI
Not to use the live SA 14-14-2 JE vaccine
unless the mouse-brain vaccine is not
available.
SA 14-14-2 has been available in most of
private facilities in big cities and some
governmental facilities and vaccinees have
to pay for them
27 December 2007 What speciﬁc MMR vaccine to use in the
EPI for 6–12 month olds (e.g., Jeryl Lynn
strain of mumps)
Stay with current MMR vaccine due to
availability problems with other types and
revisit the schedule and target ages for
measles and MMR immunization
The EPI plans to start buying the MMR Jeryl
Lynn strain in 2010
Reconsideration of the schedule for
hepatitis B immunization in infants of
hepatitis B carrier mothers
Change schedule for infants from 2 months
of age to 1 month for the second hepatitis B
dose (ﬁrst dose at birth remains the same)
The recommendation was distributed to all
health care facilities nation-wide, and has
been implemented
Selection of public education messages
about HPV immunization
Use already available educational materials
developed by medical associations
The educational material has been put on
the EPI website
al ﬂu
with
NHSO
5
r
f
(
F
pWhat high-risk groups should receive
seasonal ﬂu vaccine besides health workers
Season
people
by the
.4. Factors and evidence considered by the ACIP in developing
ecommendationsTo formulate policy recommendations, the ACIP reviews many
actors, including both “policy issues” and “programmatic issues”
Fig. 1). Policy issues include the mortality and morbidity from the
ig. 1. Factors and evidence considered by the ACIP in developing immunization
olicy.vaccine should be given to
chronic illnesses and funded
People with chronic illness have been
receiving seasonal ﬂu vaccine since 2008
disease in both the general Thai population and in speciﬁc risk
groups; the effectiveness and feasibility of alternative controlmea-
sures; as well as evidence from both published and unpublished
sources on the safety, efﬁcacy, and effectiveness of the vaccine,
including clinical trial results. The ACIP also routinely reviews pub-
lished andunpublished economic analyses concerning the vaccines
under consideration, including cost-effectiveness and cost-beneﬁt
analysis. However, the results of economic analyses are only one
factor that the ACIP considers in developing recommendations.
Once policy issues are reviewed, the ACIP then considers pro-
grammatic issues to determine the feasibility of incorporating the
vaccine into existing EPI programs. These issues can include the
available supply of the vaccine and whether its presentation and
logistical requirements (e.g., volume and cold chain requirements)
are not too burdensome for the EPI program to handle. The Work-
ing Group or Secretariat may also gather information from mass
media (e.g., newspapers), non-governmental organizations (NGOs)
andother sources to get an indication of thepublic’s views concern-
ing the disease and the vaccine in question. The Working Groups
may present options for the ACIP to consider, such as whether to
introduce the vaccine nationally, to wait for additional data or for
the vaccine price to decrease before considering its introduction,
or not to introduce the vaccine.
The quality of the data and their origin are also considered by
the Committee, although there are as yet no written rules or cri-
teria for judging the quality or relevance of data. The ACIP prefers
local evidence (from Thailand), especially concerning disease and
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conomic burden (e.g., the number of cases, incidence rates, deaths,
isability), as well as cost-effectiveness or cost-beneﬁt of vaccina-
ion. When these data are not available for the disease in question,
he ACIP may recommend that local studies be conducted before
ntroduction of the vaccine is considered. This was the case for
ib vaccine, for which the ACIP recommended in the 1990s that
prospective Hib disease burden study and economic evaluation
e conducted in Thailand before further consideration to introduce
he vaccine into the infant EPI schedule. Both studies were then
onducted [12] and a decision not to introduce the vaccine was
ade by the Committee in 2008.
Data on a vaccine’s safety and immunogenicity or efﬁcacy in
he local population are also preferred, especially in cases where
he distribution of genotypes of the disease vary from country to
ountry (and thus the vaccine’s coverage of strains) or in cases
here there aregenetic differences in responses to avaccine among
opulations. For example, before replacing DPT and monovalent
epatitis B vaccines with the tetravalent DPT-hepatitis B vaccine,
he ACIP used data from a pilot study in one province to examine
he vaccine’s safety and immunogenicity in the local population, as
ell as logistical issues.
When data from Thailand are not available and local stud-
es are not considered feasible or necessary, the Committee may
se data from other countries, if they are considered applicable
o Thailand. In some cases where data are lacking or inadequate,
he opinion of ACIP members or other experts are used to make
ecommendations. Information about new ACIP recommendations
hat is published in ofﬁcial letters or in the ofﬁcial immunization
eference book usually does not describe in detail the methods
sed in developing recommendations, but does describe the evi-
ence used to inform these recommendations, such as the results
f clinical trials, case–control studies, case series, expert opinion,
r cost-effectiveness analyses.After formulation by the Working Group, the draft recommen-
ations are subjected to further extensive reviewbyACIPmembers,
taff of the DDC, and members of the Working Group. Working
roup or ACIP members may identify a need for additional data,
orrections in the data, or modiﬁcations in the interpretation ofvisory Committee on Immunization Practice.
the data, and members may critique and challenge the opinions of
experts. The Working Group then compiles all of these comments
and views in an iterative process and presents options for action to
the ACIP for ﬁnal consideration.
5.5. Role of the ACIP in the ultimate decision-making process
While the government is not obligated to implement recom-
mendations made by the ACIP, to date it has never rejected any
ACIP recommendation. However, sometimes the recommendation
cannot be implemented immediately, due to operational or pro-
grammatic considerations. For example, the ACIP agreed in 1999
that the EPI use the combination DPT-hepatitis B vaccine in place
of separate DPT and hepatitis B vaccines. However, due to concerns
about the programmatic feasibility of this change, including the
high vaccine price and supply issues, since therewas only oneman-
ufacturer producing the combination vaccine at that time, the DDC
requested that the implementation of the new recommendation be
delayed. The switch to the combination vaccine was subsequently
implemented nation-wide in 2007, after the vaccine price had been
reduced and more manufacturers had entered their DPT-hepatitis
B vaccine onto the market.
6. Information dissemination and the process for
approving ACIP recommendations
The minutes of each ACIP meeting are distributed to all Com-
mittee members, who are allowed to suggest revisions before the
minutes are ﬁnalized. These minutes are reviewed again at the
next ACIP meeting. The meeting minutes are not posted for the
public, but individuals and organizations can request them in writ-
ing, if they clearly state the speciﬁc reasons for their request. Most
requests are from researchers conducting research on related top-
ics, but such requests are rare.
If a new vaccine is recommended for introduction, the Depart-
ment of Disease Control will then prepare a proposal and budget
for approval by the MoPH and then by the NHSO, which oversees
the national health insurance plan. As shown in Fig. 2, the bud-
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et for introduction of the new vaccine must be approved by the
abinet and ﬁnally by the Parliament. Once approved, the national
ntroduction of the vaccine may still take one or more years, how-
ver, due to the time required to revise the immunization reference
anual, train health worker staff, procure an adequate supply of
he vaccine, plan and implement public information campaigns
nnouncing the new policy, and other activities to prepare for the
ew vaccine introduction.
Once approved, the new recommendations are distributed in
n ofﬁcial letter or in a revised edition of the immunization ref-
rence manual to all public health facilities in the country and
osted online on the website of the DDC. The new recommenda-
ions are also announced in annual refresher courses conducted
y the national EPI for all health workers involved in immuniza-
ions.
. Factors related to the success of the ACIP and remaining
hallenges
For many years, the ACIP has played a key role in guiding deci-
ions related to vaccine use and immunization in Thailand and
he Committee is considered an important factor in the success
f the country’s national immunization program. There are a num-
er of factors contributing to the success of the Committee. These
nclude: its formal establishment by the Minister of Public Health;
he multi-disciplinary expertise among its members; and the fact
hat the Secretariat consists of those responsible for implementing
he national immunization program.
However, the ACIP has a number of limitations which could be
ddressed to further strengthen the Committee and how it func-
ions. These limitations and possible areas of improvement include
he following:
1) There are no regulations or laws stipulating that all
immunization-related policy decision must ﬁrst be considered
by the ACIP. There have therefore been instances in which new
immunization policies were enacted without consideration by
the Committee.
2) Other ways of reaching decisions at ACIP meetings, such as tak-
ing a vote, should be considered as an alternative to reaching a
consensus. This is because some Committee members may not
feel free to express their views independently.
3) More representatives from several other relevant ﬁelds and
segments of society, including health economist, pharmacists,
nurses, and consumer groups, could be considered for mem-
bership on the Committee.
4) Once a new vaccine is on the market, the ACIP should put a
discussion of the vaccine and its possible introduction into the
EPI on itsmeetingagenda, regardlessof the current affordability
of the vaccine or other concerns that policymakers may have,
since these can be addressed by other government agencies.
This couldhelp to avoid the longdelays between the availability
of the vaccine in the private sector market and its introduction
into the EPI.
5) There should be written rules concerning conﬂicts of inter-
est among ACIP members. In addition, a Steering Committee
[
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should be established to review all nominees, including pos-
sible conﬂict of interest issues, and to monitor conﬂict of
interest matters once the nominees become members of the
Committee.
(6) Increasing the independence of the ACIP from theMoPH should
be considered. For example, the Chair of the ACIP is the Direc-
tor General of the Department of Disease Control (DDC), and
the ACIP’s mandate is to advise the DDC and the MoPH. This
situation may affect the independence of the ACIP and bias its
decisions in the direction that the DDC and MoPH would like it
to go.
(7) Clear and speciﬁc criteria or guidelines for decision-making
when considering the introduction of new vaccines would be
useful for the Committee. Examples are speciﬁc criteria on
the level of disease burden that is considered high; how cost-
effectiveness for a vaccine is deﬁned; and the threshold at
which a new vaccine is considered affordable.
Acknowledgments
Wewish toacknowledgeDr. Sujarti Jetanasen,Dr. PrayuraKuna-
sol, Dr. Supamit Chunsuttiwat, and Denise DeRoeck. The three
authors of this paper are all members of the Thai ACIP.
Conﬂict of interest statement
The authors state that they have no conﬂict of interest.
References
[1] EconomyWatch. Thailand Economy. http://www.economywatch.com
[accessed 20.10.2009].
[2] Bhunbhu T. Expanded programme on immunization in Thailand. Reviews of
Infectious Diseases 1989;2(Suppl. 3):s514–7.
[3] Chokpaiboolkit K, Tritsananont M, Chunsuttiwat S, Tammapornpilas P, editors.
Vaccine and immunization 2007. Bangkok: The War Veterans Organization of
Thailand; 2007 [in Thai language].
[4] National Health Security Ofﬁce (NHSO). History of the National Health Secu-
rity Ofﬁce. http://www.nhso.go.th/NHSOFront/SelectViewFolderAction.do?
folder id=000000000000016 [accessed 4.01.2010].
[5] Thammapornpilas P, Rasdjarmrearnsook A-O, editors. Vaccine coverage sur-
vey in expanded program on Immunization Program, 2008. Bangkok: The War
Veterans Organization of Thailand; 2009 [in Thai language].
[6] Secretariat Ofﬁce of the Thai National Vaccine Committee. National Vaccine
Policy and Strategic Plan 2005. Bangkok: The War Veterans Organization of
Thailand; 2005 [in Thai language].
[7] World Health Organisation (WHO). Vaccine Introduction Guidelines, adding
vaccine to a national immunization programme: decision and implementation.
Geneva: Expanded Programme on Immunization of the Department of Immu-
nization, Vaccines and Biologicals; 2005 [Ordering code: WHO/IVB/05.18].
[8] World Health Organisation (WHO). WHO Position Paper on Haemophilus
inﬂuenzae typeb conjugate vaccines.Weekly Epidemiological Record 2006;81:
445–52.
[9] World Health Organisation (WHO). WHO Position Paper on 23-valent pneu-
mococcal polysaccharide vaccine. Weekly Epidemiological Record 2008;83:
373–84.
10] World Health Organisation (WHO). WHO Position Paper on rotavirus vaccines.11] WorldHealthOrganisation (WHO).WHOPositionPaperon Japaneseencephali-
tis vaccines. Weekly Epidemiological Record 2006;81:331–40.
12] Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks
A, et al. Prospective population-based incidence of Haemophilus inﬂuenzae
type b meningitis in Thailand. Vaccine 2004;22:975–83.
